FDA Approved: CARDIOLITE — Supplemental Application (Lantheus Medical Imaging, Inc.)

View source ↗

Summary

FDA approved a supplemental application for CARDIOLITE from Lantheus Medical Imaging, Inc., updating labeling and indications for the radiopharmaceutical.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Coronary Artery Disease
• Ischemic Heart Disease

Drugs mentioned

• CARDIOLITE (TETRAKIS(2-METHOXYISOBUTYLISOCYANIDE)COPPER(I) TETRAFLUOROBORATE)

Snippet

SUPPL AP for CARDIOLITE (TETRAKIS(2-METHOXYISOBUTYLISOCYANIDE)COPPER(I) TETRAFLUOROBORATE)